214837-30-6

Upstream product

• 214837-07-7 (3S,4S)-<1-(3,4-dimethoxybenzyl)-2-oxo-4-<(R)-2-oxo-1,3-dioxololan-3-yl>azetidin-3-yl>carbamic acid benzyl ester 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 145574-13-6 benzyl (1S,4S,5S)-6-(3,4-dimethoxybenzyl)-4-hydroxy-7-oxo-2,6-diazabicyclo<3.2.0>heptane-2-carboxylate 

Downstream Products

• 145827-51-6 (1S,5R)-2--7-oxo-2,6-diazabicyclo<3.2.0>heptane-6-sulfonic acid 
• 357916-36-0 (2S,3R)-3-tert-butoxycarbonylaminopyrrolidine-1,2-dicarboxylic acid 1-(9H-fluoren-9-ylmethyl) ester 
• 595579-93-4 (1S,5R)-7-Oxo-2,6-diaza-bicyclo[3.2.0]heptane-2,6-dicarboxylic acid 2-benzyl ester 6-tert-butyl ester 
• 145574-16-9 benzyl (1S,5R)-7-oxo-2,6-diazabicyclo<3.2.0>heptane-2-carboxylate 
• 145574-15-8 benzyl (1S,5R)-6-(3,4-dimethoxybenzyl)-7-oxo-2,6-diazabicyclo<3.2.0>heptane-2-carboxylate 

Relevant academic research and scientific papers

A virosome-mimotope approach to synthetic vaccine design and optimization: Synthesis, conformation, and immune recognition of a potential malaria-vaccine candidate

An optimized cyclic peptidomimetic (see picture) of the NPNA-repeat region in the circumsporozoite (CS) protein of P. falciparum was designed. When delivered to the immune system on human-compatible viruslike particles (virosomes), the mimetic effectively

Structure-based design of β-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams

Bridged monobactams are novel, potent, mechanism-based inhibitors of class C β-lactamases, designed using X-ray crystal structures of the enzymes. They stabilize the acyl-enzyme intermediate by blocking access of water to the enzyme-inhibitor ester bond.